Related Experiment Video

Updated: Feb 1, 2026

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

13.9K

AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer

Masahiro Yamamoto1, Shuhei Suzuki2,3, Keita Togashi2,4

  • 1Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata, Japan masahiro@med.id.yamagata-u.ac.jp m-okada@med.id.yamagata-u.ac.jp.

Anticancer Research
|December 4, 2018
PubMed
Abstract

Insights

AS602801, a c-Jun N-terminal kinase (JNK) inhibitor, enhances chemotherapy effectiveness in ovarian cancer stem cells (CSCs). It reduces survivin, an anti-apoptotic protein, making CSCs more sensitive to carboplatin and paclitaxel.

Area of Science:

  • Oncology
  • Cancer Stem Cell Biology
  • Pharmacology

Background:

  • Cancer stem cells (CSCs) possess tumor-initiation and metastatic potential.
  • AS602801, a novel c-Jun N-terminal kinase (JNK) inhibitor, is known to suppress CSC properties.
  • The chemosensitizing effect of AS602801 on CSCs remains unexplored.

Purpose of the Study:

  • To investigate the potential of AS602801 to chemosensitize ovarian cancer stem cells (CSCs).
  • To explore the underlying mechanisms of AS602801-mediated chemosensitization in combination with standard chemotherapeutics.

Main Methods:

  • Utilized A2780 CSLC, an ovarian cancer-derived CSC line.
  • Examined the combined effects of AS602801 with carboplatin and paclitaxel.
  • Investigated the molecular mechanisms, including survivin expression.

Main Results:

  • AS602801 significantly chemosensitized A2780 CSLC cells to carboplatin and paclitaxel.
  • AS602801 treatment led to reduced expression of survivin, an anti-apoptotic protein.
  • Survivin inhibition, both pharmacologically and genetically, also chemosensitized cells, and this effect was observed across various CSCs and non-CSCs.

Conclusions:

  • AS602801 demonstrates chemosensitizing effects on ovarian CSCs by downregulating survivin.
  • AS602801 is a promising therapeutic candidate targeting chemoresistance, tumor initiation, and metastasis in CSCs.
Keywords:
Drug repositioningdrug resistancerepurposing

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.0K

Related Concept Videos

Adult Stem Cells01:33

Adult Stem Cells

Stem cells are undifferentiated cells that divide and produce more stem cells or progenitor cells that differentiate into mature, specialized cell types. All the cells in the body are generated from stem cells in the early embryo, but small populations of stem cells are also present in many adult tissues including the bone marrow, brain, skin, and gut. These adult stem cells typically produce the various cell types found in that tissue—to replace cells that are damaged or to continuously...
33.9K
Embryonic Stem Cells00:58

Embryonic Stem Cells

Embryonic stem (ES) cells are undifferentiated pluripotent cells, meaning they can produce any cell type in the body. This gives them tremendous potential in science and medicine since they can generate specific cell types for use in research or to replace body cells lost due to damage or disease.
32.5K
Embryonic Stem Cells00:57

Embryonic Stem Cells

Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...
5.1K
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells01:18

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

A stem cell is an unspecialized cell that can divide without limit as needed and can, under specific conditions, differentiate into specialized cells.
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
4.5K
Induced Pluripotent Stem Cells01:13

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
28.1K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.0K